Price
No data yet.
Social Signal Score
Analyst Ratings
43 analystsRevenue
$6.55B+42.97%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Julie Sawyer Montgomery
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 59,000
- Beta
- 0.80
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 3.67
Financials
Revenue
$6.55B+43.0%Net Income
$1.24B+65.3%EBITDA
$1.27B+22.5%Free Cash Flow
$1.63B+238.7%EPS (diluted)
$1.75+63.6%Shares Outstanding (diluted)
706.80M+0.7%Operating Expenses
$2.59BCash & Debt
$5.68BReturn of Capital
$281.00MRevenue by Segment (annual)
$24.57BDividend per Share
$0.40Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $24.57B | $3.61B | $5.07 |
| 2024 | $23.88B | $3.90B | $5.33 |
| 2023 | $23.89B | $4.76B | $6.44 |
| 2022 | $26.64B | $7.21B | $9.80 |
| 2021 | $29.45B | $6.43B | $8.77 |
| 2020 | $22.28B | $3.65B | $4.97 |
| 2019 | $17.91B | $2.56B | $3.48 |
| 2018 | $17.05B | $2.65B | $3.78 |
| 2017 | $18.33B | $2.49B | $3.58 |
| 2016 | $16.88B | $2.55B | $3.69 |
| 2015 | $14.43B | $2.60B | $4.81 |
| 2014 | $19.91B | $2.60B | $3.70 |
| 2013 | $19.12B | $2.69B | $3.87 |
| 2012 | $18.26B | $2.30B | $3.45 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DHR's reported EPS growth of 3.0% a year over 13 years.
- EPS in 5 years
- $5.88
- Implied price
- $264.53
- Return from $226.30
- 3.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $131.52 — -41.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 31 | 38 | 45 | 52 | 59 |
|---|---|---|---|---|---|
| -7.0% | -13.5% | -9.9% | -6.8% | -4.1% | -1.7% |
| -2.0% | -8.9% | -5.1% | -1.8% | 1.0% | 3.6% |
| 3.0% | -4.2% | -0.3% | 3.2% | 6.2% | 8.9% |
| 8.0% | 0.4% | 4.6% | 8.2% | 11.4% | 14.2% |
| 13.0% | 5.1% | 9.4% | 13.2% | 16.5% | 19.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
81+61.20%Social Signal Score
Mentions (52)
- News (Marketaux)manilatimes.net·2d ago·Positive
Lendmark Financial Services Earns National Recognition for Turning Talent Into Long-Term Careers Selected from a field of leading employe[+314 characters]
View source ↗ - Newsprnewswire.com·2d ago·Neutral
…g autonomous science through smart scientific instruments and an interoperable agentic ecosystem WASHINGTON, Nov. 20, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced a strategic partnership with Microsoft to support the development of smart scientific instruments and an interoperable agentic ecosystem that connects technologies across Danaher while remaining open to the broader laboratory ecosystem, helping scientists move from scientific questions to experimental evidence f…
View source ↗ - News (RSS)seekingalpha·5d ago·Positive
Danaher Corporation (DHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Danaher Corporation (DHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript Danaher Corporation (DHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsmarketbeat.com·13d ago·Positive
Danaher CEO Sees Faster Growth Ahead, With AI and Acquisitions in Focus Danaher NYSE: DHR President and CEO Julie Sawyer Montgomery said the company is aiming for faster core growth and market share gains through stronger commercial execution, innovation and acquisitions, as it pursues a leadership position in life sciences and diagnostics.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Danaher Corporation (DHR) Presents at 2026 UBS Global Healthcare Conference Transcript Danaher Corporation (DHR) Presents at 2026 UBS Global Healthcare Conference Transcript
View source ↗ - Newsdefenseworld.net·19d ago·Negative
Danaher Corporation $DHR Holdings Trimmed by Bank Julius Baer & Co. Ltd Zurich Bank Julius Baer and Co. Ltd Zurich trimmed its stake in Danaher Corporation (NYSE: DHR) by 67.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 101,849 shares of the conglomerate's stock after selling 211,896 shares during the period. Bank Julius Baer
View source ↗ - Newsprnewswire.com·20d ago·Neutral
Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences WASHINGTON, Nov. 2, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Julie Sawyer Montgomery, will be presenting at the UBS Global Healthcare Conference in Palm Beach, Florida on Monday, November 9, 2026 at 11:45 a.m. ET and Jefferies Global Healthcare Conference in London, UK on November 17, 2026 at 10:00 a.m.
View source ↗ - Newszacks.com·26d ago·Positive
Danaher (DHR) Upgraded to Buy: Here's Why Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newszacks.com·31d ago·Neutral
LH vs. DHR: Which Stock Is the Better Value Option? Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
View source ↗ - Newsseekingalpha.com·31d ago·Positive
Danaher Q3 Recap: Decent Results, Still A Hold Danaher Corporation is rated hold, as the stock trades at a small premium and offers an 8.85% expected return, below my threshold. Q3 earnings showed solid performance: revenue up 8.3% YoY to $6.55B, adjusted EPS of $2.11, and strong segment growth, especially in Diagnostics. Key headwinds include respiratory revenue volatility and pricing pressure from China's volume-based procurement, despite some recent positive trends.
View source ↗ - News (RSS)seekingalpha·32d ago·Neutral
Danaher forecasts 2027 core growth of 4%-5% ex respiratory while lifting 2026 adjusted EPS guidance to $8.57-$8.62
View source ↗ - News (RSS)seekingalpha·32d ago·Positive
Danaher Corporation (DHR) Q3 2026 Earnings Call Transcript
View source ↗ - News (RSS)fool·32d ago·Positive
Danaher: 3 Key Takeaways for Long-Term Investors Portfolio reshaping complete, management now pivots to organic growth and disciplined acquisitions to compound returns.
View source ↗ - News (Marketaux)gurufocus.com·32d ago·Positive
Q3 2026 Danaher Corporation Earnings Call Transcript At this time, I would like to welcome ev[+241 characters]
View source ↗ - Newsfool.com·32d ago·Positive
Why Danaher Stock Bounced Higher Today It beat analyst estimates for both revenue and profitability. Its full-year earnings guidance also topped the pundit consensus.
View source ↗ - News (RSS)fool·32d ago·Positive
Danaher (DHR) Q3 2026 Earnings Call Transcript Revenue beat $6.6B with 8.5% growth; free cash flow hit $1.6B for the quarter.
View source ↗ - News (RSS)seekingalpha·32d ago·Neutral
Danaher Corporation 2026 Q3 - Results - Earnings Call Presentation
View source ↗ - Newsseekingalpha.com·32d ago·Positive
Danaher Corporation (DHR) Q3 2026 Earnings Call Transcript Danaher Corporation ( DHR ) Q3 2026 Earnings Call October 21, 2026 8:00 AM EDT Company Participants Rachel Vatnsdal Olson - Vice President of Investor Relations Julie Montgomery - President, CEO & Director Matthew Gugino - Executive VP & CFO Conference Call Participants Doug Schenkel Vijay Kumar - Evercore ISI Institutional Equities, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Operon Research, LLC Sc…
View source ↗ - Newsfool.com·32d ago·Positive
Danaher: 3 Key Takeaways for Long-Term Investors Danaher raised full-year earnings per share guidance to $8.57 to $8.62. Biotechnology orders grew mid-teens during the third quarter.
View source ↗ - Newsseekingalpha.com·32d ago·Neutral
Danaher Q3 Review: Interested To See What The New Management Will Bring Danaher Corporation delivered mixed Q3 results, with revenue up 8.3% y/y but growth driven mainly by acquisitions and tariff refunds. Adjusted operating margin reached 29%, exceeding guidance, yet organic growth and profitability improvements remain modest and partly non-recurring. Management's Q4 guidance implies lower-than-expected EPS, and the new CEO signals a need for stronger growth and operational execution.
View source ↗ - News (Marketaux)gurufocus.com·32d ago·Positive
Danaher (DHR) Shares Slip After Q3 Revenue Miss Despite EPS Beat On October 21, 2026, Danaher Co[+314 characters]
View source ↗ - Newszacks.com·32d ago·Positive
DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line Danaher's third-quarter earnings beat estimates by 9.9%, driven by stronger Biotechnology profitability, while it raised its 2026 adjusted earnings outlook.
View source ↗ - News (Marketaux)gurufocus.com·32d ago·Positive
Danaher Corp (DHR) Raises 2026 Earnings Guidance Amid Strong Valuation Signals On October 21, 2026, Danaher Co[+210 characters]
View source ↗ - Newszacks.com·32d ago·Neutral
Danaher (DHR) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsprnewswire.com·32d ago·Neutral
Danaher Reports Third Quarter 2026 Results WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the third quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.
View source ↗ - Newsdefenseworld.net·35d ago·Negative
Danaher Corporation $DHR Shares Bought by Birch Hill Investment Advisors LLC Birch Hill Investment Advisors LLC boosted its stake in shares of Danaher Corporation (NYSE: DHR) by 9.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 40,549 shares of the conglomerate's stock after acquiring an additional 3,553 shares during the
View source ↗ - Newsdefenseworld.net·36d ago·Neutral
7,604 Shares in Danaher Corporation $DHR Bought by Beaumont Asset Management L.L.C. Beaumont Asset Management L.L.C. purchased a new stake in shares of Danaher Corporation (NYSE: DHR) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 7,604 shares of the conglomerate's stock, valued at approximately $1,685,000. A number of other institutional investors and hedge funds have also recently
View source ↗ - Newszacks.com·37d ago·Neutral
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? DHR's Q3 results are due Oct. 21, with growth in Biotechnology, Diagnostics and Life Sciences expected to boost revenues, while rising costs and currency headwinds weigh on earnings.
View source ↗ - Newszacks.com·37d ago·Neutral
Seeking Clues to Danaher (DHR) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics Evaluate the expected performance of Danaher (DHR) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
View source ↗ - Newszacks.com·39d ago·Neutral
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report? Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - Newszacks.com·39d ago·Neutral
Danaher (DHR) Earnings Expected to Grow: Should You Buy? Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsprnewswire.com·39d ago·Neutral
…ether NVIDIA AI technologies and Danaher's scientific instruments, laboratory workflows and data WASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced a collaboration with NVIDIA to advance autonomous science and help accelerate the pace of scientific discovery. As part of Danaher's broader effort to shape the future of AI-enabled science, the companies are working to combine Danaher's scientific instrumentation, automation technologies, laboratory workflow so…
View source ↗ - News (RSS)investing·41d ago·Neutral
Danaher adds two directors, expands board to 13 members
View source ↗ - Newsprnewswire.com·41d ago·Neutral
Danaher Announces Appointments of Daniel Comas and Robert Hershberg to Board of Directors WASHINGTON, Oct. 12, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") today announced the appointment of Daniel L. Comas and Robert Hershberg, M.D.
View source ↗ - News (RSS)channelnewsasia·46d ago·Negative
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027
View source ↗ - Newsprnewswire.com·46d ago·Negative
…ng AI, automation and innovation from across Danaher's ecosystem of industry-leading technologies WASHINGTON, Oct. 7, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced plans to launch its first AI-powered autonomous lab, designed to help researchers develop custom antibodies and other molecular tools faster and more efficiently. Expected to operate at scale in early 2027, the lab will combine artificial intelligence, robotics and technologies from several Danaher operating com…
View source ↗ - Newszacks.com·48d ago·Neutral
ELV or DHR: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical Services sector have probably already heard of Elevance Health (ELV) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
View source ↗ - Newsprnewswire.com·52d ago·Neutral
Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer WASHINGTON, Oct. 1, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") announced that, effective today, Julie Sawyer Montgomery has assumed the roles of President and Chief Executive Officer and has joined Danaher's Board of Directors, as previously announced on August 3, 2026. Since joining the Company in 2017, Ms.
View source ↗ - Newszacks.com·53d ago·Positive
DHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace? Danaher's Biotechnology segment posts 4% sales growth, but tough comparisons and shipment timing could test its momentum.
View source ↗ - Newsetftrends.com·53d ago·Positive
The Top HealthTech Questions Landing on Our Desks Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
View source ↗ - News (RSS)seekingalpha·59d ago·Neutral
Danaher Isn't Anything Special, Even After Absorbing Masimo
View source ↗ - News (Marketaux)seekingalpha.com·59d ago·Neutral
Danaher Isn't Anything Special, Even After Absorbing Masimo (NYSE:DHR) Danaher Isn't Anything Special, Even After Absorbing Masimo (NYSE:DHR)
View source ↗ - Newsprnewswire.com·61d ago·Neutral
Danaher Schedules Third Quarter 2026 Earnings Conference Call WASHINGTON, Sept. 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2026 on Wednesday, October 21, 2026 beginning at 8:00 a.m.
View source ↗ - News (RSS)yahoo·64d ago·Neutral
Cardinal Health (NYSE:CAH) Vs Danaher Corporation (NYSE:DHR) – Here’s The One Jim Cramer Said Did Better
View source ↗ - Newsprnewswire.com·68d ago·Neutral
Danaher Announces Quarterly Dividend WASHINGTON, Sept. 15, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 30, 2026 to holders of record on September 30, 2026.
View source ↗ - Newszacks.com·68d ago·Positive
ELV or DHR: Which Is the Better Value Stock Right Now? Investors with an interest in Medical Services stocks have likely encountered both Elevance Health (ELV) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - News (Marketaux)economictimes.indiatimes.com·75d ago·Neutral
DHR Holdings leases 1.8 lakh sq ft in Bengaluru (You can now subscribe to our (You can [+333 characters]
View source ↗ - Newszacks.com·89d ago·Neutral
Danaher Rides on Strength in Biotechnology Segment: Will It Sustain? DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.
View source ↗ - News (RSS)yahoo·91d ago·Positive
Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?
View source ↗ - News (Marketaux)finance.yahoo.com·91d ago·Positive
Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside? Danaher (NYSE:DHR) is [+327 characters]
View source ↗ - Newsseekingalpha.com·100d ago·Positive
Danaher: 2027 Growth Reacceleration Should Drive Upside Danaher is rated a Buy, with revenue growth expected to accelerate in 2027 as respiratory headwinds fade and bioprocessing shipments recover. DHR's valuation is reasonable, trading at a 12% discount to its five-year average P/E, supported by strong recurring revenues and operational excellence. Life Sciences segment shows robust recovery, with 5.5% core growth and margin expansion, driven by improved pharma spending and biotech funding.
View source ↗
Earnings
Wed, Jan 27(in 2 months)
Consensus estimate $2.49 per share
Typical surprise +9.8% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Oct 21$2.11 vs $1.92beat
- Tue, Jul 21$1.94 vs $1.85beat
- Tue, Apr 21$2.06 vs $1.94beat
- Wed, Jan 28$2.23 vs $2.16beat
- Tue, Oct 21$1.89 vs $1.72beat
- Tue, Jul 22$1.80 vs $1.64beat
Estimates and results for DHR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DHR officers and directors.
- Bought
- —
- Sold
- $26.1m
0 trades
9 trades
- Mcgrew Matthewsold
- Milosevich Gregory Msold
- Bouda Christophersold
- Bouda Christophersold
- Mcgrew Matthewsold
- Mcgrew Matthewsold
- Blair Rainersold
- Blair Rainersold
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (27d later)Buy$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (28d later)Sell$15,001 - $50,000
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (26d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 13, 2026 (27d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 13, 2026 (38d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 13, 2026 (41d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 13, 2026 (40d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 8, 2026 (36d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed May 11, 2026 (13d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 10, 2026 (36d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Jan 16, 2026 (29d later)Sell$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (260d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Dec 12, 2025 (29d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Nov 17, 2025 (41d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (42d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Oct 22, 2025 (27d later)Sell$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Oct 15, 2025 (42d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2025 (18d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
